UBS Global Healthcare Conference
Logotype for Myriad Genetics Inc

Myriad Genetics (MYGN) UBS Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Myriad Genetics Inc

UBS Global Healthcare Conference summary

10 Nov, 2026

Q2 pressures and guidance

  • Q2 revenue fell 11% and ASP fell 9%; prenatal volume and average revenue per test remained soft, while hereditary cancer reimbursement pressure also weighed on results.

  • Updated guidance assumes Q2-suppressed ASP persists through H2, no improvement in prenatal volume, and no benefit from new products or added sales capacity.

  • H1 revenue multiplied by two is a couple million dollars above the updated guidance midpoint; historically, H2 contributes about 52% of annual revenue.

  • Guidance assumes new salespeople remain at Q2 efficiency levels; productivity typically takes quarters to build.

Reimbursement and operational initiatives

  • Revenue Cycle Management Optimization is targeting execution across people, processes and tools to reduce billing friction and improve collections; progress was reported over the preceding months.

  • Hereditary cancer pressure from several payers was not attributed to medical-policy changes; a separate, medium- to long-term effort aims to align payer policy, guidelines and clinical practice.

  • Project Ascend is a multiyear effort spanning commercial operations, revenue cycle and other processes, targeting cost savings, revenue synergies and scalability; initial benefits are expected in 2027, with actions continuing into 2028.

  • Portfolio decisions intended to materially strengthen revenue, profitability, gross margin and liquidity were expected to be shared within the next couple of months.

  • Investment and portfolio choices are increasingly centered on the Cancer Care Continuum, with decisions assessing patient and provider value, customer relationships, competitive capabilities and profitability.

Hereditary cancer and prenatal testing

  • MyRisk volume growth had continued for several quarters; management cited potential to sustain high-single-digit to low-double-digit growth and a $7B market, including ~$5B in unaffected patients with less than one-third penetration.

  • Growth drivers include an updated polygenic risk score, a dedicated unaffected-market sales team established April 1, market-activation campaigns and 2026 guideline additions for ovarian, colorectal and gastric cancers.

  • Prenatal performance was below expectations amid intensified competition and sales-force changes; stabilization signals include a smaller quarterly decline, new-customer volume offsetting losses, then overall volume stability and growth.

  • FirstGene launched about a month before the conference, combining maternal and fetal screening from one blood draw as early as eight weeks, with results within 14 days; returning customers and positive early feedback were noted.

  • FirstGene uses existing billing codes; average revenue per test exceeds the legacy prenatal portfolio with consistent COGS, making tests accretive to gross margin and profitability.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Myriad Genetics